Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease

The advent of immune checkpoint inhibitors (ICIs) for cancer therapy has heralded increasing frequency of immune-related adverse events including endocrinopathies, hepatitis, colitis and rarely myocarditis and myasthenia gravis (MG). The heterogeneity in clinical presentations regardless of organ-sp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Case Rep
Hauptverfasser: Leaver, Phillip John, Jang, Helena Sung-In, Vernon, Stephen Thomas, Fernando, Suran Loshana
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7228148/
https://ncbi.nlm.nih.gov/pubmed/32404371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-232920
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge